Complications of systemic chemotherapy as treatment of retinoblastoma.
Benz
M S
MS
Bascom Palmer Eye Institute, Miami, FL 33136, USA.
Scott
I U
IU
Murray
T G
TG
Kramer
D
D
Toledano
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009503:Neutropenia / Q000139:chemically induced*; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D019572:Retinal Neoplasms / Q000188:drug therapy*; D012175:Retinoblastoma / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced*; D014750:Vincristine / Q000008:administration & dosage
D009943:Organophosphorus Compounds; D003561:Cytarabine; C061400:etoposide phosphate; D014750:Vincristine; D005047:Etoposide; D016572:Cyclosporine; D016190:Carboplatin; D008727:Methotrexate